688393 Guangzhou LBP Medicine Science & Technology
- 15.51
- +0.47+3.13%
Guangzhou LBP Medicine Science & Technology News
Guangzhou LBP Medicine Science & Technology (688393.SH) shareholders Zhujigaokejia and others plan to reduce their shareholding by no more than 2%.
Guangzhou LBP Medicine Science & Technology (688393.SH) announced that the company recently received shareholder Zhujiaogao Special Excellent, Chongqing Gao Tejia, Hangzhou Enuo Technology's notice of reduction of holdings. ...
An Biping (688393.SH): Nanjing Qianjing plans to reduce its holdings by no more than 2%
On May 24, Ge Longhui (688393.SH) announced that due to shareholders' capital requirements, Nanjing Qianjing now plans to reduce its holdings of the company's shares by no more than 1,871,300 shares (including capital) through bulk transactions, to no more than 2% of the company's current total share capital, within 3 months after 3 trading days from the date of disclosure of this announcement. If there is a limit on the window period for trading stocks during the reduction period, the reduction of shares will be stopped.
2023 equity distribution of Anbiping (688393.SH): $0.15 per share
An Biping (688393.SH) issued an announcement. The company's 2023 equity allocation will be implemented: before the plan is implemented...
Anbipine (688393.SH): No technology related to human stem cells yet
Gelonghui, May 10丨An Biping (688393.SH) said on the interactive platform that the company's main business includes cancer screening and accurate diagnosis, mainly for hospital pathology departments, and has not yet involved human stem cell-related technology.
Chinese Drug Regulator Grants Certificates to Two LBP Medicine Science & Technology Products
Guangzhou LBP Medicine Science & Technology (SHA:688393) obtained a medical device registration certificate from China's National Medical Products Administration for two products, according to the com
Anbiping (688393.SH) obtained medical device registration certificate for 2 in vitro diagnostic reagents
Anbiping (688393.SH) announced that the company recently received “Medical Devices...” issued by the State Drug Administration
Anbiping (688393.SH)'s net profit of 7.99 million yuan in the first quarter increased 2.17% year over year
Gelonghui, April 29丨An Biping (688393.SH) announced that in the first quarter of 2024, the company's revenue was 101 million yuan, up 11.82% year on year; net profit attributable to shareholders of listed companies was 7.99 million yuan, up 2.17% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 4.8 million yuan, up 78.59% year on year.
Guangzhou LBP Medicine Science & Technology's (SHSE:688393) Shareholders Have More To Worry About Than Only Soft Earnings
The market rallied behind Guangzhou LBP Medicine Science & Technology Co., Ltd.'s (SHSE:688393) stock, leading do a rise in the share price after its recent weak earnings report. We think that shareh
LBP Medicine Scraps Convertible Bonds Issuance Plans
Guangzhou LBP Medicine Science & Technology (SHA:688393) withdrew plans to issue convertible bonds, the company said in its filing on the Shanghai Stock Exchange. The Chinese diagnostic product manufa
An Biping (688393.SH): Net profit in 2023 fell 6.18% year on year, and plans to pay 10 to 1.5 yuan
Gelonghui, April 22丨An Biping (688393.SH) released its 2023 annual report. Operating revenue for the reporting period was 497 million yuan, down 1.99% year on year; net profit attributable to shareholders of listed companies was 40.572 million yuan, down 6.18% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 353.13,800 yuan, down 13.74% year on year; basic earnings per share were 0.43 yuan. The company plans to distribute a cash dividend of 1.5 yuan (tax included) for every 10 shares to all shareholders.
LBP Medicine Gets Certificate for HER2 Antibody Reagent
Guangzhou LBP Medicine Science & Technology (SHA:688393) received a device registration certificate for its HER2 antibody reagent from China's National Medical Products Administration, according to th
Anbiping (688393.SH) received the HER2 antibody reagent (immunohistochemistry) medical device registration certificate
An Biping (688393.SH) issued an announcement. The company recently received the “Medical...” issued by the State Drug Administration
Guangzhou LBP Medicine Science & Technology Co., Ltd.'s (SHSE:688393) Shares Climb 30% But Its Business Is Yet to Catch Up
Those holding Guangzhou LBP Medicine Science & Technology Co., Ltd. (SHSE:688393) shares would be relieved that the share price has rebounded 30% in the last thirty days, but it needs to keep going to
Anbiping (688393.SH) products obtained medical device registration certificate
Anbiping (688393.SH) announced that the company recently received “Medical Devices...” issued by the State Drug Administration
Anbiping (688393.SH) performance report: 2023 net profit of 403.01 million yuan, a year-on-year decrease of 5.61%
Gelonghui, Feb. 23: An Biping (688393.SH) announced the 2023 Annual Results Report. During the reporting period, the company achieved operating income of 497.295 million yuan, a year-on-year decrease of 1.99%; realized net profit attributable to owners of the parent company of 403.01 million yuan, a year-on-year decrease of 5.61%; realized net profit attributable to owners of the parent company after deducting non-recurring gains and losses, of 36.44,800 yuan, a year-on-year decrease of 10.99%.
Risks Still Elevated At These Prices As Guangzhou LBP Medicine Science & Technology Co., Ltd. (SHSE:688393) Shares Dive 26%
The Guangzhou LBP Medicine Science & Technology Co., Ltd. (SHSE:688393) share price has fared very poorly over the last month, falling by a substantial 26%. The drop over the last 30 days has cappe
An Biping (688393.SH): The company has been re-certified as a high-tech enterprise
Gelonghui, January 26丨An Biping (688393.SH) announced that it recently received the “Notice on Filing the Third Batch of High-tech Enterprises with 2023 Certification Report” issued by the Office of the National High-tech Enterprise Certification and Management Leading Group. According to the “Third Batch of High-tech Enterprises Filing List for 2023 Certification Report by Guangdong Certification Authority”, An Biping has passed the high-tech enterprise certification. The certificate number is: GR202344011947. The certificate number is:. The certification period is December 28, 2023, and is valid for three years. This certification is a high-tech enterprise in the Anbi Plain
Anbiping (688393.SH): The company's HPV28 full classification test kit was successfully selected for collection group A
Gelonghui January 8 丨 An Biping (688393.SH) Investor Relations Activity Record Sheet shows that the company's HPV28 full classification test kit was successfully selected for collection Group A, and we can also see that the price was drastically reduced after collection. Looking at the overall market, firstly, the reduction in the price of HPV DNA test kits will reduce the burden of medical expenses on the public, and secondly, it will bring about industry integration and purification of the business environment. We have determined that the reduction in fees is accompanied by HPV DNA testing as the initial screening method for cervical cancer. Whether it is the clinical side or the screening side for both cancers, the HPV DNA test volume will usher in another one
Anbiping (688393.SH) obtained 58 various qualifications in October-December
An Biping (688393.SH) issued an announcement. The company and its subsidiaries received domestic approval from October to December 2023...
Anbiping (688393.SH): and its subsidiary obtained 48 domestic medical device registration/filing certificates from October to December 2023
Gelonghui, January 8, 丨 An Biping (688393.SH) announced that the company and its subsidiaries obtained 48 domestic medical device registration/filing certificates and 10 intellectual property qualifications from October to December 2023.
Analysis
Price Target
No Data
